Maze Therapeutics (MAZE) Liabilities and Shareholders Equity (2024 - 2026)

Maze Therapeutics has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $419.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 26.1% year-over-year to $419.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 169.0% YoY) and the FY2025 annual result came in at $397.1 million, up 65.1% from the prior year.
• Liabilities and Shareholders Equity rose to $419.7 million in Q1 2026 per MAZE's latest filing, from $397.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $422.1 million in Q3 2025 and troughed at $240.5 million in Q4 2024.
• A 3-year average of $352.6 million and a median of $365.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity jumped 65.1% in 2025, then grew 26.1% in 2026.
• Over 3 years, Liabilities and Shareholders Equity stood at $240.5 million in 2024, then surged by 65.1% to $397.1 million in 2025, then advanced by 5.69% to $419.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $419.7 million, $397.1 million, and $422.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.